Software-based, real-time AI dashboard providing continuous risk estimates for unplanned cesarean delivery during labor.
Software-based, real-time AI dashboard providing continuous risk estimates for unplanned cesarean delivery during labor.: The intervention is a software-based, real-time clinical decision-support dashboard (ORACLE-AI) integrated into the electronic health record and used during intrapartum care. The system continuously analyzes admission characteristics and dynamic labor data, including serial cervical examinations, uterine activity, and cardiotocography (CTG) annotations, to generate individualized estimates of the probability of unplanned cesarean delivery. Risk estimates are updated automatically every 5-7 minutes and displayed as a continuous numeric percentage with a graphical time trend and 95% confidence intervals. The dashboard is visible only to the clinical care team and is advisory in nature; it does not provide prescriptive recommendations or automated alerts, and it does not replace clinical judgment. All obstetric management decisions, medications, and procedures follow standard institutional protocols at the discretion of the treating clinicians. No drugs, implants, or additional procedures
Study summary
ORACLE-AI is a single-center, open-label, randomized clinical trial comparing primiparous women managed with a real-time machine-learning dashboard against a concurrent control group receiving standard intrapartum care. Participants are randomized 1:1 at the onset of labor. The intervention group has the AI dashboard visible in their electronic health record, while the control group does not. The primary hypothesis is that the use of continuous AI-based risk estimates will be non-inferior to standard care in terms of unplanned cesarean\–delivery rates (uCD), with potential secondary benefits in maternal and neonatal outcomes.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Age ≥ 18 years at the time of consent
* Able and willing to provide written informed consent
* Nulliparous (no prior birth ≥ 24 weeks' gestation)
* Singleton live pregnancy
* Cephalic (vertex) fetal presentation
* Gestational age ≥ 37+0 weeks
* Admitted to the labor ward in labor (cervical dilation ≥ 3 cm with regular contractions) or undergoing induction or augmentation of labor with intent to proceed to vaginal delivery
* Planned trial of labor (no scheduled or elective cesarean delivery)
* Receiving intrapartum care at Hadassah-Hebrew University Medical Center, Mount Scopus campus
Exclusion Criteria:
* Planned or elective cesarean delivery prior to labor admission
* Multifetal gestation
* Non-cephalic fetal presentation
* Gestational age \< 37+0 weeks
* Major fetal anomaly expected to affect labor or neonatal management
* Contraindication to vaginal delivery (e.g., placenta previa, invasive placentation, prior uterine surgery precluding labor)
* Category III fetal heart rate tracing on admission requiring immediate delivery
* Maternal hemodynamic instability or other life-threatening condition necessitating urgent surgical or critical-care intervention
* Inability to provide informed consent due to cognitive impairment, intoxication, or other incapacity
* Concurrent participation in another interventional obstetric study that could confound outcomes or increase risk
Primary outcome measure(s)
Primary Endpoint: unplanned cesarean delivery rates. — From randomization at labor admission to delivery (time of birth), up to 7 days. Unplanned cesarean delivery is defined as any cesarean delivery performed after the onset of labor or during induction of labor, in participants randomized to the study, excluding scheduled or elective cesarean deliveries. The outcome is assessed from the time of randomization at labor admission through delivery and is recorded as a binary variable (yes/no) per participant, based on electronic health record documentation.
Trial sites (1)
Facility
City
Region
Status
Hadassah Mt. Scopus Hebrew University Medical Center
Jerusalem
Israel
Recruiting
More Hadassah Medical Organization trials in Israel
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
